Chinese Society of Clinical Oncology guidelines for BC version 2022 have highlighted that, for patients with HER2-positive status, the recommended approach for new adjuvant treatment consists of either anthracycline plus paclitaxel or non-anthracycline plus trastuzumab ± pertuzumab as the first-line treatment. The gene discussed is ERBB2; the disease is breast cancer.